Beam Therapeutics Slides 9% as BEAM-302 Data Fails to Impress
BEAM sits 39% above its 52-week low of $19.355 on elevated volume (2.4× avg).
Summary
Beam Therapeutics shares fell 9% to $26.88 after updated Phase 1/2 data for BEAM-302 in AATD showed total AAT levels declining from 16.1 uM at 9 months to 13.5-14.4 uM at 12 months, despite the treatment being well tolerated. The data were not numerically better than prior results, disappointing investors who had hoped for stronger efficacy. The company plans to pursue an accelerated approval pathway based on FDA feedback and will enroll 50 additional patients to support a future BLA. This follows the earlier presentation of the same data at ERS 2026, but the market reaction and specific 12-month figures are new. The decline in AAT levels over time raises questions about durability of effect, a key concern for gene editing therapies.
At the time of this announcement, BEAM was trading at $26.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $19.36 to $38.26. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.